期刊文献+

临床药师参与1例间变性大细胞淋巴瘤患儿严重剥脱性皮炎的病例分析 被引量:2

Medication analysis of clinical pharmacists participating in one child patient with severe exfoliative dermatitis
下载PDF
导出
摘要 目的分析1例间变性大细胞淋巴瘤患儿产生严重剥脱性皮炎的原因,探索临床药师在指导用药中的作用。方法系统分析1例严重剥脱性皮炎患儿的给药、皮炎发生过程、处理及预后。结果间变性大细胞淋巴瘤及联合用药均可引起剥脱性皮炎。结论临床药师参与患者的治疗与监护,可减少不良反应的发生,保障患者的用药安全。 Objective To investigate the relationship between anaplastic large cell lymphoma and delayed severe exfoliative dermatitis,in order to explore the role of clinical pharmacists in guiding drug use.Methods Systematically analyzes the drug administration process,drug combination,and the occurrence and treatment of dermatitis of a case of exfoliative dermatitis.Results The severe exfoliative dermatitis was resulted by anaplastic large cell lymphoma itself and the drugs used in treatment.Conclusion Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia,can reduce the occurrence of adverse reactions,to ensure the safety of patients.
作者 张淑萍 冷佳蔚 张静 ZHANG Shuping;LENG Jiawei;ZHANG Jing(Air Force Qingdao Center of Aviation Medical Evaluation and Training,Qingdao 266071,China;Shandong Institute for Food and Drug Control,Jinan 250101,China;Jinan Children Hospital,Jinan 250022,China)
出处 《药学研究》 CAS 2018年第5期298-300,共3页 Journal of Pharmaceutical Research
关键词 间变性大细胞淋巴瘤 剥脱性皮炎 临床药师 药学监护 Anaplastic large cell lymphoma Exfoliative dermatitis Clinical pharmacists Pharmaceutical care
  • 相关文献

参考文献6

二级参考文献47

  • 1黄玉斌.381例别嘌醇不良反应分析[J].中国药物应用与监测,2005,2(1):32-34. 被引量:23
  • 2本刊编辑部.系列问答106——何谓别嘌醇过敏综合征?[J].药物不良反应杂志,2006,8(5):396-396. 被引量:11
  • 3国家药典委员会.临床用药须知(化学药和生物制剂卷)[S]北京:人民卫生出版社,2005731.
  • 4Hung SI,Chung WH ,Liou LB,et al. HLA-B * 5801 al-lele as a ge- netic marker for severe cutaneous adverse re-actions caused by allo- pminol. Proc Natl Acad Sci U S A,2005,102(11) : 4134-4139.
  • 5Tassaneeyakul W,Jantararoungtong T,Chen P,et al. Strong associ- ation between HLA-B * 5801 and allopurinol-induced Stevens-John- son syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Ge-nomics,2009,19(9) : 704-709.
  • 6RoujeauJC, KellyJP, NaldlL, et. Medication use and the risk of? Stevens-Johnson syndrome or toxic epidermal necmlysis . N Engl J Med, 1995,333 (24) : 1600-1607.
  • 7Lee HY ,Pang SM, Thamotharampillai T. Anopurinol--induced Ste- vens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermato1,2008,59 (2) : 352-353.
  • 8Nassif A, Bensussan A, Boumsell L,et al. Toxic epidermal necroly- sis: effeetor cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol,2004,114(5) : 1209-1215.
  • 9Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity [ J]. Pharmacogenomics. 2012, 13 ( 11 ) : 1285 -306.
  • 10Chung W H, Hung S I, Hong H S, et al. Medical genetics: amarker for Stevens-Johnson syndrome [ J ]. Nature, 2004, 428 (6982) :486.

共引文献31

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部